Mumbai, June 29 -- The company plans to manufacture the tablets in strengths of 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg.

Cenobamate is a next-generation antiseizure medication indicated for the treatment of partial-onset seizures in adults. Clinical studies have demonstrated significant seizure reduction and high seizure freedom rates in patients with inadequately controlled epilepsy, positioning the drug as an important advancement in epilepsy treatment.

Commenting on the development, Anil Jain, managing director of Bajaj Healthcare, said the SEC recommendation marks a significant regulatory milestone and reflects the company's progress in developing Cenobamate tablets. He added that Bajaj Healthcare will continue to work with...